DIA_CENTRAL:T2D Treatment Pattern in Central Europe

February 23, 2023 updated by: Boehringer Ingelheim

CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries

This is a non-interventional study using existing data including medical chart review.

Study Overview

Status

Completed

Conditions

Diabetes Mellitus, Type 2

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

4083

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Bulgaria
- - Byala, Bulgaria, 7100
    - MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903
  - Dimitrovgrad, Bulgaria, 6400
    - MC "Diamedical 2013" OOD, Center Nr.: 35902
  - Dobrich, Bulgaria, 9300
    - MBAL- Dobrich AD, Center Nr.: 35916
  - Dupnitsa, Bulgaria, 2600
    - Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904
  - Plovdiv, Bulgaria, 4000
    - MHAT "Medline Clinic", Center Nr.: 35911
  - Plovdiv, Bulgaria, 4030
    - MC Kuchuk Parij OOD, Center Nr.: 35906
  - Rakovski, Bulgaria, 4150
    - MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909
  - Razgrad, Bulgaria, 7200
    - "Medical Center-Razgrad"OOD, Center Nr.: 35910
  - Russe, Bulgaria, 7000
    - DCC 1 - Russe EOOD, Center Nr.: 35905
  - Sliven, Bulgaria, 8800
    - MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915
  - Sofia, Bulgaria, 1303
    - MC Polimed AD, Center Nr.: 35907
  - Sofia, Bulgaria, 1463
    - MC Gina - LZ SIMP EOOD, Center Nr.: 35918
  - Sofia, Bulgaria, 1680
    - MC "Vitaclinic" EOOD, Center Nr.: 35901
  - Sofia, Bulgaria, 1680
    - MC Kalimat EOOD, Center Nr.: 35914
  - Varna, Bulgaria, 9002
    - Acibadem City Clinic Medical Center Varna EOOD, Center Nr.: 35908
Czechia
- - Beclav, Czechia, 69002
    - Michal Brada, Center Nr.: 42001
  - Beroun, Czechia, 26656
    - Dr. Kovaová, Center Nr.: 42069
  - Bilina, Czechia, 418 01
    - Practice Dr. Alice Sýkorová, Center Nr.: 42057
  - Broumov, Czechia, 55001
    - MUDr. Alica Vesela, Center Nr.: 42030
  - Eské Budjovice, Czechia, 37001
    - EUC Klinika eské Budjovice, Center Nr.: 42052
  - Eské Budjovice, Czechia, 37011
    - Lékaský dm Géko, Center Nr.: 42059
  - Havíov, Czechia, 73601
    - Barbara Buzová, Center Nr.: 42003
  - Havíov, Czechia, 73601
    - Zaviatiová, Petra, Center Nr.: 42004
  - Hlušovice, Czechia, 78314
    - Radana Syslová, Center Nr.: 42035
  - Hoovice, Czechia, 268 31
    - Pavel Kasík, Center Nr.: 42046
  - Humpolec, Czechia, 39601
    - Practice Dr. Petr Maule, Center Nr.: 42054
  - Jihlava, Czechia, 58601
    - Mediab Jihlava s.r.o., Center Nr.: 42066
  - Karlovy Vary, Czechia, 36066
    - Practice MUDr. Gita Markofová, Center Nr.: 42053
  - Karviná - Staré Msto, Czechia, 73301
    - Dr. Konená, Center Nr.: 42036
  - Karviná-Hranice, Czechia, 73301
    - Practice Zdzislaw Wranka, Center Nr.: 42072
  - Kopivnice, Czechia, 74221
    - Pavel Tománek, Center Nr.: 42028
  - Kralupy nad Vltavou, Czechia, 27801
    - DIABET HELP s.r.o., Center Nr.: 42058
  - Krnov, Czechia, 79401
    - MUDr.Tomáš Edelsberger, Center Nr.: 42007
  - Kromiz, Czechia, 76901
    - Jitka Hasalová, Center Nr.: 42010
  - Lede Nad Sázavou, Czechia, 58401
    - árka Drinková, Center Nr.: 42038
  - Mladá Boleslav, Czechia, 29350
    - Martina Košková, Center Nr.: 42047
  - Nmice Nad Hanou, Czechia, 79827
    - Dobromila Vykoupilová, Center Nr.: 42033
  - Nový Jiín, Czechia, 74101
    - Karel Churavý, Center Nr.: 42005
  - Nymburk, Czechia, 28802
    - árka Kubánková, Center Nr.: 42048
  - Olomouc, Czechia, 772 00
    - Agentura Science Pro spol. s.r.o., Center Nr.: 42002
  - Olomouc, Czechia, 77900
    - Anna Rancová, Center Nr.: 42025
  - Opava, Czechia, 74601
    - Josef íný, Center Nr.: 42026
  - Opono, Czechia, 51773
    - MUDr.Tomáš Hrdina, Center Nr.: 42015
  - Ostrava, Czechia, 700 30
    - Dr. Šeptáková, Center Nr.: 42074
  - Ostrava, Czechia, 70200
    - Practice Dr. René Turínek, Center Nr.: 42034
  - Ostrava, Czechia, 71000
    - MUDr. Eva Raická, Center Nr.: 42024
  - Ostrava, Czechia, 72880
    - Jitka Homolová, Center Nr.: 42012
  - Ostrava Poruba, Czechia, 70800
    - Radka Nágelová, Center Nr.: 42020
  - Perov, Czechia, 75301
    - AIDIN VK s.r.o., Center Nr.: 42017
  - Plze, Czechia, 30100
    - Zdenk Jankovec, Center Nr.: 42044
  - Podbrady, Czechia, 29001
    - Diabetologická a interní ambulance, Center Nr.: 42064
  - Praha, Czechia, 10000
    - MUDr. Jana Houdová, Center Nr.: 42068
  - Praha 2, Czechia, 12143
    - Practice Dr. Milena Peterková, Center Nr.: 42063
  - Praha 4, Czechia, 14000
    - MUDr.Michala Pelikánová s.r.o., Center Nr.: 42055
  - Praha 4, Czechia, 14021
    - Markéta Hovorková, Center Nr.: 42042
  - Praha 4, Czechia, 14300
    - Jakub Hron, Center Nr.: 42043
  - Praha 5, Czechia, 15000
    - Milan Fleka, Center Nr.: 42041
  - Praha 5, Czechia, 15030
    - Jií Jón, Center Nr.: 42045
  - Praha 5, Czechia, 15030
    - Practice Dr. Lucie Kufová, Center Nr.: 42062
  - Praha 6, Czechia, 16300
    - Practice Dr. Ida Reissová, Center Nr.: 42056
  - Praha 9, Czechia, 19014
    - Barbora Diepoltová, Center Nr.: 42037
  - Píbram, Czechia, 26101
    - MUDr. Vra Prýmková, Center Nr.: 42070
  - Rumburk, Czechia, 40801
    - Practice Dr. Petronela Janeková, Center Nr.: 42065
  - Sokolov, Czechia, 35601
    - Practice Dr. Miroslav Lindovský, Center Nr.: 42051
  - Strakonice, Czechia, 38601
    - Dana Fialkoviová, Center Nr.: 42040
  - Tebí, Czechia, 674 01
    - Marek Frydrych, Center Nr.: 42008
  - Tebí, Czechia, 674 01
    - Marek Frydrych, Center Nr.: 42077
  - Uherské Hradišt, Czechia, 68601
    - Diabetologická ambulance s.r.o., Center Nr.: 42076
  - Vlašim, Czechia, 25801
    - Dr. Hrmová, Center Nr.: 42073
  - Vrchlabí, Czechia, 54301
    - Lubomír Kudlej, Center Nr.: 42050
  - Vsetín, Czechia, 75501
    - AdiaMed s.r.o., Center Nr.: 42009
  - Zlín, Czechia, 76001
    - EUC Klinika Zlín a.s., Center Nr.: 42075
  - Zlín, Czechia, 76001
    - Robin Urbánek, Center Nr.: 42029
Hungary
- - Budapest, Hungary, 1106
    - Bajcsy-Zsilinszky Kórház és Rendelintézet, Center Nr.: 36019
  - Budapest, Hungary, 1204
    - Jahn Ferenc Dél-pesti Kórház és Rendelintézet, Center Nr.: 36014
  - Debrecen, Hungary, 4032
    - Debreceni Egyetem Klinikai Központ, Kardiológiai Klinika, Center Nr.: 36006
  - Karcag, Hungary, 5300
    - Kátai Gábor Kórház, Diabetológia Szakrendelés, Center Nr.: 36007
  - Mátészalka, Hungary, 4700
    - Practice Dr. Lelkesi Anita, Center Nr.: 36013
  - Nagyatád, Hungary, 7500
    - Nagyatádi Kórház, Center Nr.: 36021
  - Nyíregyháza, Hungary, 4400
    - Nyírségi Diabetes Centrum, Center Nr.: 36024
  - Pécs, Hungary, 7625
    - Dr. Wagner Zoltán, Center Nr.: 36020
  - Siófok, Hungary, 8600
    - Siófoki Kórház Rendelintézet, Center Nr.: 36004
  - Sopron, Hungary, 9400
    - Soproni Gyógyközpont, Center Nr.: 36018
Poland
- - Biaystok, Poland, 15-591
    - Gabinet Diabetologiczno- Internistyczny Katarzyna Wasilewska, Center Nr.: 48011
  - Czechowice-Dziedzice, Poland, 43-502
    - NZOZ DIAMED Sp. z o.o., Center Nr.: 48061
  - Czyca, Poland, 99-100
    - Prywatny Gabinet Lekarski dr n. med. Joanna Sawer-Szewczyk, Center Nr.: 48055
  - Czyca, Poland, 99-100
    - Zespó Opieki Zdrowotnej w czycy, Center Nr.: 48054
  - Dzieroniów, Poland, 58-200
    - NZOZ Sal Med, Center Nr.: 48047
  - Gorlice, Poland, 38-300
    - Poradnia Diabetologiczna, Center Nr.: 48028
  - Jelenia Góra, Poland, 58-506
    - Indywidualna Specjalistyczna Praktyka Lekarska Piotr Piskozub Specjalista Diabetolog, Center Nr.: 48042
  - Konin, Poland, 62-504
    - NZOZ Poradnia Diabetologiczna, Center Nr.: 48038
  - Kraków, Poland, 31-548
    - Zakad Opieki Medycznej Sanatio; Sp. Z. o.o., Center Nr.: 48030
  - Kutno, Poland, 99-300
    - Prywatny Gabinet Lekarski Tomasz Wierzykowski, Center Nr.: 48053
  - Kwidzyn, Poland, 82-500
    - Indywidualna Specjalistyczna Praktyka Lekarska Magorzata Poskoska-Lemaska, Center Nr.: 48035
  - Legnica, Poland, 59-220
    - Indywidualna Specjalistyczna Praktyka Lekarska Barbara Soróbka, Center Nr.: 48001
  - Lesko, Poland, 38-600
    - Poradnia Cukrzycowa SP ZOZ w Lesku, Center Nr.: 48024
  - Lubaczów, Poland, 37-600
    - Lumed Sp. z o.o., Center Nr.: 48032
  - Lubin, Poland, 59-300
    - DIABETA-CARE Sp.z o.o., Center Nr.: 48008
  - Nako Nad Noteci, Poland, 89-100
    - Poradnia Diabetologiczna Dr. mudziska, Center Nr.: 48013
  - Nowy Scz, Poland, 33-300
    - Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Center Nr.: 48007
  - Olenica, Poland, 56-400
    - Poradnia Diabetologiczna Dr. Adamczyk-Gajda, Center Nr.: 48031
  - Orzesze, Poland, 43-180
    - MED-ART Sp. z o.o., Center Nr.: 48052
  - Ostrów Wielkopolski, Poland, 63-400
    - Indywidualna Specjalistyczna Praktyka Lekarska Wiesawa Fischer, Center Nr.: 48020
  - Parczew, Poland, 21-200
    - Prywatny Gabinet Lekarski azuka, Center Nr.: 48026
  - Stalowa Wola, Poland, 37-450
    - Powiatowy Szpital Specjalistyczny w Stalowej Woli, Center Nr.: 48056
  - Warszawa, Poland, 03-922
    - Prywatny Gabinet Lekarski dr n. med. Piotr Gryglas, Center Nr.: 48059
  - Wicbork, Poland, 89-410
    - Poradnia Diabetologiczna Szpitala Powiatowego w Wicborku, Center Nr.: 48003
  - Woomin, Poland, 05-200
    - Orodek Praktyka Lekarska Konrad Strzelczyk, Center Nr.: 48012
  - Wyszków, Poland, 07-200
    - Poradnia Diabetologiczna SPZZOZ w Wyszkowie, Center Nr.: 48067
  - Zabrze, Poland, 41-800
    - Wojewódzka Poradnia dla Chorych na Cukrzyc, Center Nr.: 48025
  - Zielona Góra, Poland, 65-001
    - Cardiomed, Center Nr.: 48019
Russian Federation
- - Barnaul, Russian Federation, 656043
    - Anturium, Center Nr.: 70036
  - Batajsk, Russian Federation, 346880
    - Central city hospital, Center Nr.: 70073
  - Chelyabinsk, Russian Federation, 454076
    - Chelyabinsk regional clinical hospital, Center Nr.: 70069
  - Ekaterinburg, Russian Federation, 620102
    - Limited Liability Company "Uralsky Medical Center", Center Nr.: 70063
  - Ekaterinburg, Russian Federation, 620144
    - Scientific and Practical Center of Specialized Types of Medical Care "Uralskij Institute of Cardiology", Center Nr.: 70079
  - Irkutsk, Russian Federation, 664049
    - Russian Medical Academy of Continuing Professional Education, Center Nr.: 70058
  - Izhevsk, Russian Federation, 426039
    - The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Center Nr.: 70037
  - Kazan, Russian Federation, 420073
    - Central City Hospital No. 18, Center Nr.: 70051
  - Kemerovo, Russian Federation, 50066
    - Kemerovo regional clinical hospital named S.V. Belyaev, Center Nr.: 70008
  - Khabarovsk, Russian Federation, 680045
    - City Polyclinic No. 16, Center Nr.: 70067
  - Kirov, Russian Federation, 610020
    - Kirov Clinical Hospital No. 7 named after V.I. Yurlova, Center Nr.: 70089
  - Krasnodar, Russian Federation, 350086
    - Krai clinical hospital Nr. 1 named after prof. S.V. Ochapovskogo, Center Nr.: 70049
  - Lipetsk, Russian Federation, 398902
    - Lipetsk Regional Hospital, Center Nr.: 70046
  - Moscow, Russian Federation, 109240
    - SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080
  - Moscow, Russian Federation, 115409
    - Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042
  - Moscow, Russian Federation, 117218
    - City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70043
  - Moscow, Russian Federation, 117218
    - City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70045
  - Moscow, Russian Federation, 127273
    - City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082
  - Moskau, Russian Federation, 117036
    - National Medical Research Center for Endocrinology, Center Nr.: 70025
  - Moskau, Russian Federation, 119034
    - Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032
  - Moskau, Russian Federation, 119034
    - Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70041
  - Moskau, Russian Federation, 119034
    - Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70081
  - Moskau, Russian Federation, 119034
    - Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70084
  - Moskau, Russian Federation, 125252
    - Vessel Clinic, Center Nr.: 70011
  - Moskau, Russian Federation, 127644
    - City Clinical Hospital named after V.V. Veresaeva of the Moscow Department of Health, Center Nr.: 70003
  - Nalchik, Russian Federation, 360051
    - City Polyclinic No. 1, Center Nr.: 70074
  - Nizhniy Novgorod, Russian Federation, 603003
    - City clinical hospital #12 of Sormovskiy district of Nizhniy Novgorod, Center Nr.: 70018
  - Nizhny Novgorod, Russian Federation, 603005
    - Privolzhsky Research Medical University, Center Nr.: 70085
  - Novokuznetsk, Russian Federation, 654027
    - Novokuznetsk City Clinical Hospital No. 1, Center Nr.: 70050
  - Novosibirsk, Russian Federation, 630007
    - AVICENNA, Center Nr.: 70065
  - Novosibirsk, Russian Federation, 630078
    - City Clinical Polyclinic #16, Center Nr.: 70056
  - Novosibirsk, Russian Federation, 6300911
    - Novosibirsk State Medical University, Center Nr.: 70059
  - Novosibirsk, Russian Federation, 630099
    - AVICENNA, Center Nr.: 70064
  - Penza, Russian Federation, 440026
    - Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095
  - Perm, Russian Federation, 614000
    - Private Clinic Salon Roden, Center Nr.: 70086
  - Perm, Russian Federation, 614010
    - City clinical hospital 5, Center Nr.: 70057
  - Perm, Russian Federation, 614010
    - City clinical hospital 5, Center Nr.: 70070
  - Rostov-on-Don, Russian Federation, 344092
    - City polyclinic #16 of the City Rostov-on-Don, Center Nr.: 70027
  - Saint Petersbug, Russian Federation, 191015
    - North-West State Medical University named after II. Mechnikov, Center Nr.: 70053
  - Saint Petersbug, Russian Federation, 191015
    - North-West State Medical University named after II. Mechnikov, Center Nr.: 70077
  - Saint Petersburg, Russian Federation, 197227
    - Medilux-TM, Center Nr.: 70005
  - Saint Petersburg, Russian Federation, 199106
    - City Pokrovskaya Hospital, Center Nr.: 70022
  - Saint-Petersburg, Russian Federation, 197022
    - First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70024
  - Saint-Petersburg, Russian Federation, 197022
    - First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70087
  - Samara, Russian Federation, 443110
    - Samara city polyclinic Nr. 9 of Oktyabrskiy district, Center Nr.: 70028
  - Samara, Russian Federation, 443111
    - Samara city consulting and diagnostic polyclinic nr. 14, Center Nr.: 70029
  - Saratov, Russian Federation, 410004
    - Clinical Hospital of the Saratov city, Center Nr.: 70090
  - Saratov, Russian Federation, 410012
    - LLC clinic "Family Doctor", Center Nr.: 70093
  - Saratov, Russian Federation, 410056
    - Multifunctional Medical Clinic "Sova", Center Nr.: 70030
  - St. Petersburg, Russian Federation, 197341
    - V.A. Almazov National Medical Research Center, Center Nr.: 70071
  - St. Petersburg, Russian Federation, 197349
    - AntMed, Center Nr.: 70034
  - St. Petersburg, Russian Federation, 197349
    - Dr. Tsiberkin, Center Nr.: 70048
  - St. Petersburg, Russian Federation, 966550
    - Zabotlivyi Doktor, Center Nr.: 70016
  - Stavropol, Russian Federation, 355045
    - Regional Endocrinological Dispensary, Center Nr.: 70078
  - Tyumen, Russian Federation, 625023
    - Tyumen State Medical University, Center Nr.: 70066
  - Ufa, Russian Federation, 450014
    - City clinical hospital, Center Nr.: 70019
  - Ulan-Ude, Russian Federation, 670031
    - City Polyclinic No.2, Center Nr.: 70062
  - Vladivostok, Russian Federation, 690017
    - Limited Liability Company "CENTER", Center Nr.: 70060
  - Vladivostok, Russian Federation, 690035
    - Regional Clinical Hospital No. 2, Center Nr.: 70092
  - Vladivostok, Russian Federation, 690105
    - Regional Clinical Hospital No. 2, Center Nr.: 70068
  - Volgograd, Russian Federation, 400001
    - Volgograd Regional Clinical Hospital No. 3, Center Nr.: 70076
  - Volgograd, Russian Federation, 400117
    - Clinical Polyclinic No.28, Center Nr.: 70040
  - Voronezh, Russian Federation, 394042
    - Voronezh City Clinical Hospital #11, Center Nr.: 70035
  - Voronezh, Russian Federation, 394077
    - State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70017
  - Voronezh, Russian Federation, 394077
    - State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70033
  - Voronezh, Russian Federation, 394077
    - State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70055

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Adult patients (18 years of age or older) with Type 2 Diabetes diagnosis, naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), DPP4i (Dipeptidyl-peptidase 4 inhibitor) or GLP1a (Glucagon-like peptide 1 agonist) at index date were chosen.

Description

Inclusion Criteria:

Written informed consent prior to participation
Female and male patients age ≥ 18 years
Patients with T2D diagnosis
Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

Exclusion Criteria:

Patients age < 18 years
Patients with diagnosis of other types of diabetes than T2D
Patients who do not provide written consent to the terms of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Other
Time Perspectives: Retrospective

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Subjects with Diabetes Mellitus, Type 2	Drug: Empagliflozin Empagliflozin Other Names: Jardiance® Synjardy® Trajenta® Jentadueto® Drug: Sodium Glucose Transporter 2 inhibitor Sodium Glucose Transporter 2 inhibitor Other Names: Jardiance® Synjardy® Trajenta® Jentadueto® Drug: Dipeptidyl-peptidase 4 inhibitor Dipeptidyl-peptidase 4 inhibitor Other Names: Jardiance® Synjardy® Trajenta® Jentadueto® Drug: Glucagon-like peptide 1 agonist Glucagon-like peptide 1 agonist Other Names: Jardiance® Synjardy® Trajenta® Jentadueto®

Group / Cohort

Intervention / Treatment

Subjects with Diabetes Mellitus, Type 2

Drug: Empagliflozin

Empagliflozin

Other Names:

Jardiance® Synjardy® Trajenta® Jentadueto®

Drug: Sodium Glucose Transporter 2 inhibitor

Sodium Glucose Transporter 2 inhibitor

Other Names:

Jardiance® Synjardy® Trajenta® Jentadueto®

Drug: Dipeptidyl-peptidase 4 inhibitor

Dipeptidyl-peptidase 4 inhibitor

Other Names:

Jardiance® Synjardy® Trajenta® Jentadueto®

Drug: Glucagon-like peptide 1 agonist

Glucagon-like peptide 1 agonist

Other Names:

Jardiance® Synjardy® Trajenta® Jentadueto®

What is the study measuring?

Primary Outcome Measures

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Investigators

Study Chair: Alexey Medvedchikov, +43180105-7896, alexey.medvedchikov@boehringer-ingelheim.com

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Prazny M, Suplotova L, Gumprecht J, Kamenov Z, Fulop T, Medvedchikov A, Rosenzweig D, Aleksandric M. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY(R) study. Cardiovasc Diabetol. 2022 Oct 8;21(1):203. doi: 10.1186/s12933-022-01631-4.

Helpful Links

Related Info

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 26, 2019

Primary Completion (Actual)

August 31, 2021

Study Completion (Actual)

August 31, 2021

Study Registration Dates

First Submitted

January 15, 2019

First Submitted That Met QC Criteria

January 15, 2019

First Posted (Actual)

January 17, 2019

Study Record Updates

Last Update Posted (Actual)

December 1, 2023

Last Update Submitted That Met QC Criteria

February 23, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

1245-0187

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).

For more details refer to: https://www.mystudywindow.com/msw/datatransparency

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

University of North Carolina, Chapel Hill
American Heart Association

Recruiting

Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine (ALIGN)

Type 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes Education

United States
ENBIOSIS BIOTECHNOLOGIES
Aydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaborators

Not yet recruiting

AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes (AIM-MET)

Type 2 Diabetes | Diabetes Mellitus Type 2

Turkey (Türkiye)
Instituto Nacional de Ciencias Medicas y Nutricion...

Active, not recruiting

Effect of an Intervention With Apple Cider Vinegar on Glycemic Variability and Lipid Profile in Patients With Type 2 Diabetes Mellitus (Apple vinegar)

Type 2 Diabetes Mellitus 2

Mexico
Endogenex, Inc.

Not yet recruiting

Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

Diabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
University of Salamanca
University of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...

Enrolling by invitation

NMES, Exercise, and Glycemic Control in Older Adults With Type 2 Diabetes (NMES4GlyCon)

Type 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes Mellitus

Portugal
Endogenex, Inc.

Not yet recruiting

Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)

Diabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
University of Colorado, Denver
Massachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaborators

Recruiting

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery (PREPARE 4 AID)

Diabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type II

United States
Kaiser Permanente
The Permanente Medical Group

Enrolling by invitation

Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy

Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)

United States
Sanofi

Completed

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (GEMELLI1)

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

Hungary, Russian Federation, Germany, Poland, Japan, United States, Finland
Steno Diabetes Center Copenhagen

Recruiting

Cognitive Screening and Multidomain Intervention Targeting Cognitive Decline in Type 2 Diabetes (The Brain Care Study)

Diabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)

Denmark

Clinical Trials on Empagliflozin

University of Illinois at Chicago

Recruiting

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin (EMPA-CKD)

Albuminuria | Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

United States
ADIUM

Completed

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions (EB-24-003)

Bioequivalance

Mexico
Instituto de Investigación Biomédica de Salamanca

Not yet recruiting

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

Chronic Kidney Disease

Spain
Ain Shams University

Completed

Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF (EMPA-DMMI)

Heart Failure | Diabete Mellitus | Remodeling, Left Ventricle

Egypt
National Taiwan University Hospital
Stanford University

Not yet recruiting

Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

Brugada Syndrome (BrS)

Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Diabetes Mellitus, Type 1

Austria, Germany
King's College London
Guy's and St Thomas' NHS Foundation Trust

Not yet recruiting

PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction (PRECISE-CMD)

Coronary Microvascular Dysfunction (CMD)
Hotel Dieu de France Hospital

Recruiting

Effect of Empagliflozin on Inflammation (EMPANTINFLAM)

PCI | CAD - Coronary Artery Disease | SGLT 2 Inhibitors | Inflamation

Lebanon
University of Sao Paulo
Medical school of the University of São Paulo (FMUSP)

Not yet recruiting

Empagliflozin Adjunctive Therapy in Bipolar Depression (EMPA-BD)

Insulin Resistance | Bipolar Disorder | Bipolar Depression

Brazil
Ain Shams University

Completed

SGLT2 Adjunct in T1D

Type 1 Diabetes | Nephropathy, Diabetic

Egypt

Outcome Measure	Measure Description	Time Frame
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported. The concomitant T2D medications reported are: Metformin Sulfonylurea Acarbose Pioglitazone Insulin Others	At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported. The reported concomitant CVD and/or chronic CKD medications are: Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) Statins Low dose aspirin Beta blockers Diuretics Others	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: Female Male	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of race are: Black Non-black	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of gender are: Female Male	At study index date 1 (i.e. between September 2018 and December 2018).
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of race are: Black Non-black	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of gender are: Female Male	At study index date 1 (i.e. between September 2018 and December 2018).
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).	At study index date 1 (i.e. between September 2018 and December 2018).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of race are: Black Non-black	At study index date 1 (i.e. between September 2018 and December 2018).
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.	At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of percentage (%) of glycosylated hemoglobin are: <8.5% ≥8.5% Missing	At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of percentage of glycosylated hemoglobin are: <8.5% ≥8.5% Missing	At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of percentage of glycosylated hemoglobin are: <8.5% ≥8.5% Missing	At study index date 1 (i.e. between September 2018 and December 2018).
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.	At study index date 1 (i.e. between September 2018 and December 2018).
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.	At study index date 1 (i.e. between September 2018 and December 2018).
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.	At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist Time Frame: At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.	At study index date 1 (i.e. between September 2018 and December 2018).

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Sampling Method

Study Population

Description

Study Plan

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Investigators

Publications and helpful links

General Publications

Helpful Links

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

IPD Plan Description

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Empagliflozin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations